Creation of a long-acting nanoformulated dolutegravir

Creation of a long-acting nanoformulated dolutegravir

Current ART for treatment of HIV-1 infection requires a strict daily regimen adherence. Herein, the authors report the manufacture and characterization of a nanoformulated dolutegravir prodrug with improved cell and tissue penetration, a remarkable apparent half-life and the potential for bimonthly...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Brady Sillman, Aditya N. Bade, Prasanta K. Dash, Biju Bhargavan, Ted Kocher, Saumi Mathews, Hang Su, Georgette D. Kanmogne, Larisa Y. Poluektova, Santhi Gorantla, JoEllyn McMillan, Nagsen Gautam, Yazen Alnouti, Benson Edagwa, Howard E. Gendelman
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/9fe938444e464eaea1e85845549ff241
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/9fe938444e464eaea1e85845549ff241

Ejemplares similares